Clinical Research Directory

Inclusion Criteria: * Post-menopausal Women * Life expectancy 3 months * Histological confirmation of ER+ breast cancer * Clinical or histological confirmation of metastatic or locally advanced disease not amenable to surgical resection * Measurable or non-measurable disease * Adequate bone marrow, renal and hepatic function * Eastern Cooperative Oncology Group (ECOG) performance status \< or equal to 2 * Progressive disease whilst receiving an aromatase inhibitor (AI) for metastatic breast cancer (MBC) * Relapsed with metastatic disease whilst receiving an AI in adjuvant setting * Up to 3 prior lines of endocrine therapy for Advanced Breast Cancer * Up to 1 line of chemotherapy for Advanced Breast Cancer * Patient willing to donate archival tumour sample * Patient willing to donate baseline blood sample * Suitable for further endocrine therapy Exclusion Criteria: * Previous treatment with fulvestrant or PI3K/mTOR(mammalian target of rapamycin )/Akt inhibitor therapy * Treatment with chemotherapy, immunotherapy or targeted, biologic or tumour embolisation within 21 days of study drug administration * Palliative radiotherapy within 7 days of study drug * Clinically significant abnormalities in glucose metabolism * Rapidly progressive visceral disease not suitable for further endocrine therapy * Known brain or leptomeningeal metastases * Any co-existing medical condition precluding trial entry including significant cardiac disease (to be defined in the protocol) * Concomitant medication unsuitable for combination with trial medication